MONTREAL, QUEBEC--(CCNMatthews - June 13, 2006) - Osta Biotechnologies Inc. (TSX VENTURE:OBI) today announced the results of a scale up clinical study involving 123 subjects for the development of a novel blood test for Alzheimer’s disease (AD). This study was conducted by Dr. Hyman Schipper, a neurologist at the Sir Mortimer B. Davis - Jewish General Hospital (JGH) and McGill University. Data from this scale up study confirm the previous results on 82 subjects which showed statistically significant difference in patients suffering from AD compared to normal healthy controls and patients with Parkinson’s disease. These results hold promise that this blood test provides a simple and reliable diagnosis of subjects suffering from early Alzheimer’s disease.
